Actualizado 28/06/2010 11:06
- Comunicado -

Kowa Company, Ltd. Grants Abbott Exclusive Rights to Market Pitavastatin Calcium, a Lipid-lowering Drug, in Australia an

Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2008 was EUR689.6 million, operating income was EUR144.7 million and net income was EUR100.4 million.

For more information about Recordati please visit http://www.recordati.com

For further information please contact: Bob Ireland, bireland@kowa.co.uk, Office Tel: +44(0)118-944-3804, Mobile: +44(0)7796-952845

Contenido patrocinado